PharmaCyte Biotech Yönetim

Yönetim kriter kontrolleri 3/4

PharmaCyte Biotech CEO'su Josh Silverman, Oct2022 tarihinde atandı, in görev süresi 2.08 yıldır. in toplam yıllık tazminatı $ 787.92K olup, şirket hissesi ve opsiyonları dahil olmak üzere 46.3% maaş ve 53.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.65% ine doğrudan sahiptir ve bu hisseler $ 86.00K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6 yıl ve 2.8 yıldır.

Anahtar bilgiler

Josh Silverman

İcra Kurulu Başkanı

US$787.9k

Toplam tazminat

CEO maaş yüzdesi	46.3%
CEO görev süresi	2.1yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	6yrs
Yönetim Kurulu ortalama görev süresi	2.8yrs

Son yönetim güncellemeleri

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

CEO Tazminat Analizi

Josh Silverman'un ücretlendirmesi PharmaCyte Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jul 31 2024	n/a	n/a	US$4m
Apr 30 2024	US$788k	US$365k	-US$17m
Jan 31 2024	n/a	n/a	-US$15m
Oct 31 2023	n/a	n/a	-US$10m
Jul 31 2023	n/a	n/a	-US$10m
Apr 30 2023	US$198k	US$188k	-US$4m

Tazminat ve Piyasa: Josh 'ın toplam tazminatı ($USD 787.92K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 647.72K ).

Tazminat ve Kazançlar: Josh 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Josh Silverman (54 yo)

2.1yrs

Görev süresi

US$787,923

Tazminat

Mr. Joshua N. Silverman, also known as Josh, is Independent Chairman of the Board of Petros Pharmaceuticals, Inc. Mr. Joshua N. Silverman, also known as Josh, serves as an Independent Director at Femasys I...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Silverman	Interim CEO	2.1yrs	US$787.92k	0.65% $ 86.0k
Carlos Trujillo	Chief Financial Officer	7.7yrs	US$586.56k	0.14% $ 17.9k
Jose Iglesias	Consulting Chief Medical Officer	4.3yrs	Veri yok	Veri yok
Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	9yrs	Veri yok	Veri yok

6.0yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim: PMCB 'un yönetim ekibi deneyimli ve deneyimlidir ( 6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Silverman	Interim CEO	2.3yrs	US$787.92k	0.65% $ 86.0k
Hans-Peter Hammes	Member of Medical & Scientific Advisory Board and Consultant	9yrs	Veri yok	Veri yok
Robert Weinstein	Independent Director	2yrs	US$290.00k	0% $ 0
Brian Salmons	Member of Medical & Scientific Advisory Board	8.5yrs	Veri yok	Veri yok
Matthias Löhr	Chairman of Medical & Scientific Advisory Board	2.8yrs	US$16.76k	Veri yok
Michael Abecassis	Independent Director	7.3yrs	US$296.00k	0.036% $ 4.8k
Wayne Walker	Independent Director	1.9yrs	US$265.00k	0% $ 0
Mark Rabe	Member of Medical & Scientific Advisory Board	no data	Veri yok	Veri yok
Jonathan Schechter	Independent Director	2.3yrs	US$290.00k	0.65% $ 86.0k
David Judd	Member of Medical & Scientific Advisory Board	5.3yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PMCB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

PharmaCyte Biotech Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

Recent updates

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

PharmaCyte Biotech, Inc. announced delayed annual 10-K filing

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş